Objectives: Polymeric nanoparticles is a promising novel drug delivery system and have advantageous in cancer therapy. Etoposide is an anticancer agent that is used in the treatment of a variety of malignancies. The present study was aimed to prepare and evaluate the Novel polymeric nanoparticles containing etoposide. Materials and Methods: 3 2 full factorial design was used to study the effect of Eudragit EPO and Pluronic F-68 on characterization of nanoparticles suspension. The polymeric nanoparticles was prepared by nano-precipitation technique. The prepared nanoparticles was evaluated by percentage yield, drug polymer compatibility using FTIR and DSC analysis, drug content, entrapment efficiency, zeta potential, particle size, SEM, XRD, In-vitro drug release studies, kinetic modeling, stability studies and in-vivo animal study. Response surface plots were studied which was generated using PCP dissolution software. Results: Scanning electron microscopic studies confirmed their porous structure with number of nanochannels. The FTIR spectra showed stable character of etoposide in mixture of polymers and revealed the absence of drug polymer interactions. DSC study revealed that drug was involved in complexation with nanoparticles. The average particle size of etoposide nanoparticles was found to be in the range of 114.4 nm to 136.7 nm. The results of zeta potential values were attained to ensure a good stability of nanosuspensions. In-vitro release of drug from nanoparticles follows peppas and showed controlled release behavior for a period of 24 h. The optimized nanoparticles were subjected to stability studies at 4ºC in refrigerator and found most suitable temperature for storage of Etoposide nanoparticles. The average targeting efficiency of drug loaded nanoparticles was found to be 41.88 ±0.030% of the injected dose in liver, 25.66±0.320% in spleen 13.82±0.090% in lungs, 4.52±0.300% in u n c o r r e c t e d p r o o f kidney and 4.18±0.490% in brain. Conclusions: The study concluded that etoposide nanoparticles could be effective in sustained release and the drug loaded nanoparticles.
INTRODUCTION
Cancer is a major public health problem in the world. There were 14. A typical example for Topoisomerase inhibitors is etoposide and it is a first line of chemotherapeutic agents that are used in the treatment of many types of cancer. The mechanism of action of Etoposide by forming a ternary complex with topoisomerase II and DNA, causing DNA breaks and cell death (1) . In addition to this, there are many side effects related to the drug (2-4), the administration of etoposide is rate limited by its low solubility in aqueous solutions (5, 6) . Therefore, finding an effective approach to facilitate the transport of drugs and to improve the bioavailability of therapeutics is necessary.
The drug candidate etoposide has variable oral bioavailability and ranging from 24-74% and has terminal half-life of 1.5 hours by intravenous route and 0.44 hours by oral route. The conventional oral therapy has drawback of low bioavailability and parenteral therapy causes inconvenience and pain to the patients as it has to be given through a continuous IV infusion over 24-34 h.
u n c o r r e c t e d p r o o f
Hence, the present study was aimed to prepare and evaluate the formulations of Eudragit EPO based nanoparticles. A nanoparticles suspension was prepared by nanoprecipitation technique using Eudragit EPO. Eudragit EPO is a cationic nonbiodegradable synthetic polymer which is used for the designing of controlled drug delivery system. 3 2 factorial designs widely used to study the effect of Eudragit EPO and Pluronic F-68 on characterization of nanoparticles suspension. The optimized formulation was subjected to lyophilisation. The prepared nanoparticles was characterized with respect to particle size and its surface morphology, Surface chargezeta potential, drug content, entrapment efficiency, In-vitro drug release studies, kinetic modeling, stability studies, animal study like biodistribution studies.
MATERIALS AND METHODS

Materials
Etoposide was a gift sample from Biocon Limited, Bangalore, India; Eudragit® EPO and HPMC K-15 were gifts from Cipla Pharmaceuticals, Mumbai, India. Pluronic® F-68 gifted from Alembic pharmaceuticals, Mumbai, India, Synthetic cellulose membrane (Mol.cut off value 12,000) was procured from Himedia Labs, Mumbai, India. All other reagents and chemicals used in this study were of Analytical Grade.
Solubility study
Solubility profile of etoposide was carried out by different solvent system such as methanol and purified water as per the standard procedure.
Preparation of Eudragit EPO based Nanoparticle
Suspension:
Nanoparticles suspensions were prepared by nanoprecipitation method.
Dissolved the 50 mg of the drug and specific amount of Eudragit®-EPO in 15 ml of methanol. The organic solution quickly injected to 40 ml aqueous solution containing A prior knowledge and understanding of the process and the variable under investigation led to preliminary experiments. Based on the preliminary data, the 3 2 factorial design was used to optimize the amount of Eudragit®-EPO (X1) and Pluronic® F-68 (X2) identify the independent variable affecting the drug content and the percentage drug encapsulation efficiency (dependent variable).
The response surfaces of the obtained result was plotted. The coded and the actual values of the experimental design are given in Table 1 . The data analysis of values obtained from various batches for drug content and entrapment efficiency was subjected to multiple regression analysis using PCP dissolution software, the equation
fitted is
Response Y = β 0 + β 1 X 1 + β 2 X 2 + β 11 X 1 2 + β 22 X 2 + β 12 X 1 X 2.... (1) Where y is the measured response; X is the level of factors; β is the coefficient computed from the responses of the formulations(quadratic form).
Physical mixtures of the drug, Eudragit EPO, Pluronic F-68 and HPMC K-15 was prepared by dry blending using same ratios as that used for the preparation of optimized batch of nanoparticles suspension 7 .
Characterization of Nanoparticles Practical yield:
Percentage practical yield Particle size analysis of nanoparticles was performed by photon correlation spectroscopy (PCS). This technique yields the mean particle diameter and particle size distribution 13 . Lyophilized nanoparticles was analyzed using Mastersizer 2000
(Malvern Instruments, Malvern, UK).
Scanning Electron Microscopy (SEM) Analysis:
Shape and Surface morphology of nanoparticles was studied by using scanning electron microscopy. SEM analysis used to determine particle shape, surface topography, texture and to examine the morphology of fractured structure. Small volume of nanoparticles suspension sufficient to mount on metal stubs using double-sided tape and coated with gold under vacuum. Stub is visualized under scanning electron microscope 14 .
Zeta Potential Measurement:
The surface of particles in suspension develops a charge due to adsorption of ions or ionization of surface groups and the charge is correspondingly dependent on both the surface chemistry and environment of the particles. The zeta potential was determined by zeta potentiometer. Sample was filled into the cell; an electrode inserted was placed under the microscope and connect them to the zeta meter.
Electrode energized and the colloids was watched to move across a grid in microscope eye piece. Track one by simply pressing track button and holding it down while the colloid traverses the grid. When the track button released, the zeta meter instantly calculates and displays the colloids zeta potential (Zetasizer, Malvern, UK ) 13 .
X ray diffractometry Analysis:
The X-ray Diffraction pattern of drug and lyophilized nanoparticles was recorded using Philips X ray diffractometer with copper target. The condition was: voltage 30kV;
u n c o r r e c t e d p r o o f current 30 mA; scanning speed -1º/min; temperature of acquisition: room temperature;
detector: scintallisation counter detector; sample holder: non-rotating holder 7 .
In-Vitro Drug Release Study:
The in-vitro drug release of drug, physical mixture and lyophilized nanoparticles was carried out by using dialysis membrane method 15 . The formulation equivalents to 50 mg of drug was poured into dialysis bags (with a cutoff of 12,000 Da, Sigma). The dialysis bag suspended in a beaker containing 100 ml of phosphate buffer pH 7.4 on a magnetic stirrer at 100 rpm, with temperature adjusted to 37±0.5°C at selected time interval. 5 ml sample was removed and replaced with fresh medium. The sample filtered through 0.45μm Millipore (Millipore filter). The samples should analyze for drug release by measuring absorbance at 286 using UV-visible spectrophotometer (Shimadzu UV-1700). The rate of etoposide release was obtained using the standard curve.
Kinetics of In-Vitro Drug Release:
PCP dissolution software was used to study the mechanism and kinetics of drug release from etoposide nanoparticles. The data obtained from invitro release study was applied into PCP dissolution software to study the various kinetic equations like zero order (% cumulative drug release Vs. time), first order (log% cumulative drug remaining Vs. time) higuchi matrix (% cumulative drug release Vs. square root of time). In order to define a model which will represent a better fit for the formulation, drug release data was further analyzed by peppas equation. The value of n indicates a measure of the primary mechanism of drug release. R 2 values was calculated for the linear curves obtained by regression analysis.
Statistical Analysis:
A prior knowledge and understanding of the process and the variable under investigation led to preliminary experiments. Based on the preliminary data, the 3 2 factorial design helpful adopted to optimize the amount of Eudragit®-EPO (x1)
and Pluronic® F-68 (x2) identify the independent variable affecting the drug content 
Where Y is the measured response; X is the level of factors; β is the coefficient computed from the responses of the formulations.
Stability Studies:
The stability studies of the optimized nanoparticles was evaluated 16 by storing formulation at 4ºC ±1ºC in refrigerator as per ICH guidelines. The nanoparticles was stored in screw capped amber-glass bottles. Physical instability like change in appearance, settling behavior was also observed. The sample is withdrawn and analyzed for its drug content, drug entrapment efficiency and in-vitro drug release profile.
In-vivo drug targeting Studies:
An experimental protocol approved by the institutional Animal Ethical Committee (APCP/IAEC/409/01) prior to start the animal studies. Experiments were performed in accordance with the current guidelines of CPCSEA.
Healthy rats weighing 200-250 g selected; a constant day and night cycle maintained and they fasted for 12 hours. The animals are divided into 3 groups, each containing 6 rats.
Group I rats treated as control (received orally 0.5% CMC dispersion only)
Group II rats received 9 mg/kg of etoposide given orally after redispersing them in 0.5% CMC dispersion;
Group III rats received nanoparticles equivalent to 9 mg/kg of etoposide given orally after redispersing them in 0.5% CMC dispersion,optimized formulation (F6) was selected for the study.
u n c o r r e c t e d p r o o f
After, 24 hour the rats were sacrificed and their liver lungs, spleen, kidney, heart and brain were isolated. Individual organs of each rat homogenized separately by using a tissue homogenizer. The tissue homogenate were made using methanol and 1.2 ml of tert-butyl methyl ether is mixed with a 0.1 ml aliquot of the tissue sample in a 2.0 ml polypropylene microtube. Then the homogenate centrifuged at 15,000 rpm for 30 min.
Collected the supernatant liquid and filtered through 0.22 µm filters and samples were analyzed by HPLC System.
RESULTS AND DISCUSSION
Spectral data of etoposide sample and standard etoposide confirmed the identity of the compound as etoposide. The solubility of etoposide in 10 mg/10 mL of solvent was carried out and it reveals that it is freely soluble in methanol, poorly soluble in water (less than mg/ml) at 37° C. Nanoprecipitation technology was selected for the production of submicron particle complying with the low aqueous solubility of etoposide.
On the basis of drug solubility and miscibility in aqueous phase, methanol was selected as a choice of solvent. The rapid diffusion of methanol from dispersed droplets into aqueous phase with subsequent evaporation leads to fast precipitation of dissolved drug and polymer in the form of nanoparticles 17 .
Drug content and encapsulation efficiency of nanoparticle suspensions were in the range of 61 to 89% and 48 to 94% respectively (Table I and As shown in Table 2 , particle size of the nanoparticle suspension was in range of 114 to 136 nm, which was almost smaller than the etoposide (1120 nm). The increase in particle size of nanoparticle suspension with decrease in polydispersity index was observed with increase in polymer content. The smaller particle size obtained at low polymer content may be due to high distribution efficiency of the internal polymersolvent phase into the external phase [20] [21] [22] . Increase in the viscosity of internal phase with increased amount of polymer also provides resistance for mass transfer in turn diffusion of polymer solvent phase into the external phase leading to particle enlargement. The zeta potential values of the nanoparticle suspension are presented in u n c o r r e c t e d p r o o f mV, was further processed to obtain dry powder. When it was compared with blank batch no significant variations in particle size and zeta potential were observed ( Table   2 ). The lyophilized nanoparticles (F6) have the average particle size of 131.4±0.057 nm.
Almost twice increase in size of particles could be due to changes in the internal structure of the particles, originated during the freeze drying process caused by the formation of ice crystal in the water phase or, more likely, to particle aggregation during freeze-drying resulting in poor redispersion 24 . Figure 3 From these above data, it showed formulation F6 released drug mostly at the end of 24 hours. The release rate of Etoposide decreased with increasing concentration of Eudragit. But increase in the rate of release found with increasing amount of pluronic.
As compared with pure drug, lyophilized nanoparticle showed significant increase in dissolution rate with maximum and complete drug release with F6 formulation.
However, lyophilization retarded the drug release, the retardation of drug release of lyophilized formulation is probability due to the aggregation of the particles in lyophilization, but still particles exhibited size below 1 micrometer.The kinetics of in-vitro drug release was determined by applying the drug release data to various kinetic models such as zero order, first order, Higuchi and Korsmeyer-Peppas. The result obtained was shown in Table 3 .
u n c o r r e c t e d p r o o f
The optimized nanoparticle suspension subjected to stability study at 4 ± 1°C.
During stability study at 4 ± 1°C, no significant difference in drug content (87.69 ± 0.043%), encapsulation efficiency (93.32 ± 0.015%) and in-vitro drug release (97.92 ± 0.037%) was observed over the period of 1 year. The stability results are shown in Table 4 . There is no significant difference in Physical instability like change in appearance, settling behavior was also observed. figure 11 . The drug loaded nanoparticles showed preferential drug targeting to liver followed by spleen, lungs, kidney and brain.
CONCLUSION:
Generally, oral etoposide administration compared to intraveneous administration may result in an improvement of patient's quality of life and reduced costs. Several studies confirmed comparable safety and efficacy of oral and intravenous etoposide.
However, a greater use of oral etoposide is limited by its incomplete and variable bioavailability. The study utilizes the particle engineering to improve primary properties Each data point is the mean ± SD of 3 experiments. 
